Commentary

Video

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

Author(s):

Harry Erba, MD, PhD,James K. McCloskey, MD

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

Related Videos
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Minoo Battiwalla, MD, MS
Justin Kaner, MD
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Related Content
Paula G. O’Connor, MD, chief medical officer, Nurix Therapeutics
October 22nd 2024

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Jorge Cortes, MD
October 17th 2024

Asciminib Yields Promising Efficacy vs SOC Agents in CML

Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University
May 6th 2024

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

FDA
October 16th 2024

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

Ahmed Hamdy, MD, chief executive officer, Vincerx
October 11th 2024

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies